Standard of Care
177Lu-TLX591-002
Phase 3 small_molecule terminated
Quick answer
Standard of Care for Metastatic Prostate Cancer is a Phase 3 program (small_molecule) at Telix Pharmaceuticals Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Telix Pharmaceuticals Ltd
- Indication
- Metastatic Prostate Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- terminated